Inovio Pharmaceuticals Announces Q4 Results, Stock Down 28%

Inovio Pharmaceuticals (NASDAQ: INO) has been one of the most volatile biotech stocks on the market as the company works on developing a potential COVID-19 coronavirus vaccine. After the markets closed on Thursday, Inovio released its fourth-quarter and 2019 full-year financial results.

As can be expected for an early-stage biotech stock, revenues were minimal overall, with the company reporting significant net losses. Total revenue came in at just $279,000 for the quarter, a significant decrease from the $2.5 million reported in Q4 2018. Inovio's net loss for the quarter came in at $37.7 million, which has slightly worsened from last year's $33 million net loss.

Image source: Getty Images.

Continue reading

Source Fool.com